Lindsay Sonstein1, Carlos Clark2, Susan Seidensticker3, Li Zeng4, Gulshan Sharma2. 1. Department of Internal Medicine, University of Texas Medical Branch, Galveston. Electronic address: Lksonste@utmb.edu. 2. Department of Internal Medicine, University of Texas Medical Branch, Galveston. 3. Department of Quality and Patient Safety, University of Texas Medical Branch, Galveston. 4. Department of Industrial and Manufacturing Systems Engineering, University of Texas, Arlington.
Abstract
BACKGROUND: Clinical practice guidelines recommend 40-60 mg of prednisone equivalent for 10-14 days for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the amount of corticosteroid prescribed varies widely in clinical practice. Using the electronic health record, we implemented an evidence-based order set to standardize treatment of patients hospitalized with acute exacerbations of COPD. METHODS: This is a pre- and post-intervention study on patients hospitalized between January 1, 2009 and September 30, 2012 with primary discharge diagnosis of COPD (International Classification of Diseases, 9(th) Revision code: 491.xx, 492.xx, and 496) and receipt of at least one dose of corticosteroid at our tertiary care hospital. Data on baseline demographics, dose of corticosteroid in prednisone equivalent administered during the first 48 hours and during the entire hospitalizations were collected from the electronic health record. Evidence-based guidelines were used to build and implement acute exacerbations of COPD management electronic ordersets in our electronic health record, Epic (Verona, WI). We divided the study into 2 time periods (January 1, 2009 through February 28, 2011 as pre- [n = 203] and March 1, 2011 through September 30, 2012 as post-intervention periods [n = 217]). The primary outcome measure was corticosteroid dose administered in the first 48 hours. Secondary outcome measures were corticosteroid dosage during the entire hospitalization, length of stay, hospital follow-up rates, and 30-day readmission rates. RESULTS: A total of 420 patients with acute exacerbations of COPD were included in the study. In the post-intervention period, the median amount of corticosteroid used in the first 48 hours was significantly reduced (306.2 mg vs 156.25 mg, P < .0001), as was that used during the entire hospitalization (352.5 mg vs 175 mg, P < .0001). There was no difference in hospital follow-up rates, length of stay, or 30-day readmission rates between the 2 periods. CONCLUSIONS: Evidence-based electronic ordersets improve compliance with clinical practice guidelines and reduce the total dose of corticosteroid administered in patients hospitalized with acute exacerbations of COPD.
BACKGROUND: Clinical practice guidelines recommend 40-60 mg of prednisone equivalent for 10-14 days for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the amount of corticosteroid prescribed varies widely in clinical practice. Using the electronic health record, we implemented an evidence-based order set to standardize treatment of patients hospitalized with acute exacerbations of COPD. METHODS: This is a pre- and post-intervention study on patients hospitalized between January 1, 2009 and September 30, 2012 with primary discharge diagnosis of COPD (International Classification of Diseases, 9(th) Revision code: 491.xx, 492.xx, and 496) and receipt of at least one dose of corticosteroid at our tertiary care hospital. Data on baseline demographics, dose of corticosteroid in prednisone equivalent administered during the first 48 hours and during the entire hospitalizations were collected from the electronic health record. Evidence-based guidelines were used to build and implement acute exacerbations of COPD management electronic ordersets in our electronic health record, Epic (Verona, WI). We divided the study into 2 time periods (January 1, 2009 through February 28, 2011 as pre- [n = 203] and March 1, 2011 through September 30, 2012 as post-intervention periods [n = 217]). The primary outcome measure was corticosteroid dose administered in the first 48 hours. Secondary outcome measures were corticosteroid dosage during the entire hospitalization, length of stay, hospital follow-up rates, and 30-day readmission rates. RESULTS: A total of 420 patients with acute exacerbations of COPD were included in the study. In the post-intervention period, the median amount of corticosteroid used in the first 48 hours was significantly reduced (306.2 mg vs 156.25 mg, P < .0001), as was that used during the entire hospitalization (352.5 mg vs 175 mg, P < .0001). There was no difference in hospital follow-up rates, length of stay, or 30-day readmission rates between the 2 periods. CONCLUSIONS: Evidence-based electronic ordersets improve compliance with clinical practice guidelines and reduce the total dose of corticosteroid administered in patients hospitalized with acute exacerbations of COPD.
Authors: Adam Wright; Joshua C Feblowitz; Justine E Pang; James D Carpenter; Michael A Krall; Blackford Middleton; Dean F Sittig Journal: Int J Med Inform Date: 2012-07-18 Impact factor: 4.046
Authors: Peter K Lindenauer; Penelope Pekow; Shan Gao; Allison S Crawford; Benjamin Gutierrez; Evan M Benjamin Journal: Ann Intern Med Date: 2006-06-20 Impact factor: 25.391
Authors: Sigrun A Johannesdottir; Erzsébet Horváth-Puhó; Olaf M Dekkers; Suzanne C Cannegieter; Jens Otto L Jørgensen; Vera Ehrenstein; Jan P Vandenbroucke; Lars Pedersen; Henrik Toft Sørensen Journal: JAMA Intern Med Date: 2013-05-13 Impact factor: 21.873
Authors: David J Ballard; Gerald Ogola; Neil S Fleming; Brett D Stauffer; Bradley M Leonard; Rainer Khetan; Clyde W Yancy Journal: Int J Qual Health Care Date: 2010-10-08 Impact factor: 2.038
Authors: Peter K Lindenauer; Penelope S Pekow; Maureen C Lahti; Yoojin Lee; Evan M Benjamin; Michael B Rothberg Journal: JAMA Date: 2010-06-16 Impact factor: 56.272
Authors: D E Niewoehner; M L Erbland; R H Deupree; D Collins; N J Gross; R W Light; P Anderson; N A Morgan Journal: N Engl J Med Date: 1999-06-24 Impact factor: 91.245
Authors: Jörg D Leuppi; Philipp Schuetz; Roland Bingisser; Michael Bodmer; Matthias Briel; Tilman Drescher; Ursula Duerring; Christoph Henzen; Yolanda Leibbrandt; Sabrina Maier; David Miedinger; Beat Müller; Andreas Scherr; Christian Schindler; Rolf Stoeckli; Sebastien Viatte; Christophe von Garnier; Michael Tamm; Jonas Rutishauser Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Dustin W Ballard; Anthony S Kim; Jie Huang; David K Park; Mamata V Kene; Uli K Chettipally; Hilary R Iskin; John Hsu; David R Vinson; Dustin G Mark; Mary E Reed Journal: Ann Emerg Med Date: 2015-09-08 Impact factor: 5.721
Authors: Swati Gulati; Aline N Zouk; Jonathan P Kalehoff; Christopher S Wren; Peter N Davison; Denay Porter Kirkpatrick; Surya P Bhatt; Mark T Dransfield; James Michael Wells Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-07-27